R. S. Heist, L. V. Sequist, and J. A. Engelman, Genetic changes in squamous cell lung cancer: a review, J Thorac Oncol, vol.7, pp.924-933, 2012.

M. Larrayoz, R. Pio, M. J. Pajares, I. Zudaire, D. Ajona et al., Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype, EMBO Mol Med, vol.6, pp.539-550, 2014.

D. H. Johnson, L. Fehrenbacher, W. F. Novotny, R. S. Herbst, J. J. Nemunaitis et al., Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer, J Clin Oncol, vol.22, pp.2184-2191, 2004.

G. Scagliotti and R. Govindan, Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer, Oncologist, vol.15, pp.436-446, 2010.

R. L. Kendall and K. A. Thomas, Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor, Proc Natl Acad Sci U S A, vol.90, pp.10705-10709, 1993.